A drug used to treat non-small cell lung cancer that has spread to other parts of the body and is anaplastic lymphoma kinase (ALK) positive. It is used in patients whose cancer got worse during treatment with crizotinib (a type of anticancer drug) and at least one other ALK inhibitor or during treatment with alectinib or ceritinib (other ALK inhibitors). It is also being studied in the treatment of other types of cancer. Lorlatinib blocks certain proteins made by the ALK gene. Blocking these proteins may stop the growth and spread of cancer cells. Lorlatinib is a type of tyrosine kinase inhibitor. Also called Lorbrena.